Skip to main content

Table 1 Number (%) of patients with potential anticholinergic adverse events by system organ class and preferred term (safety population) (Table 3 of [36], reproduced by permission)

From: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?

System organ class/preferred term

Placebo (n = 182)

Aclidinium 200 μg (n = 183)

Aclidinium 400 μg (n = 177)

Cardiac disorders

 Tachycardia

0

0

1 (0.6)

 Arrhythmia

1 (0.5)

0

0

 Bradycardia

2 (1.1)

0

0

 Palpitations

0

2 (1.1)

0

 Increased heart ratea

0

2 (1.1)

0

Eye disorders

 Transient blindness

0

1 (0.5)

0

 Reduced visual acuity

0

1 (0.5)

0

Gastrointestinal disorders

 Constipation

3 (1.6)

1 (0.5)

0

 Dry mouth

1 (0.5)

2 (1.1)

3 (1.7)

Infections and infestation disorders

 Urinary tract infection

0

3 (1.6)

1 (0.6)

Nervous system disorders

 Optic neuritis

0

0

1 (0.6)

Renal and urinary disorders

 Urinary retention

0

0

1 (0.6)

 Urinary incontinence

1 (0.5)

0

0

  1. aInvestigations is the system organ class for this preferred term